While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.
The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.
Your daily dose of the clinical news you may have missed.
Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.
Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.
Your daily dose of the clinical news you may have missed.
Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.
The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.